MONTREAL, Quebec and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. ('Milestone”) (Nasdaq: MIST) today announced that it has commenced an underwritten public offering (the 'Offering”) of its common shares, accompanying Series A warrants to purchase common shares (the 'Series A Warrants”) and accompanying Series B warrants to purchase common shares (the 'Series B Warrants”), and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, accompanying Series A Warrants and accompanying Series B warrants. All securities to be sold in the Offering will be sold by Milestone. The Offering is subject to market and other conditions and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.